The limitation of anti-vascular endothelial growth factor treatment for wet age-related macular degeneration
10.3760/cma.j.issn.1005-1015.2020.02.017
- VernacularTitle:抗血管内皮生长因子药物治疗渗出型老年性黄斑变性的局限性研究现状
- Author:
Huijuan XU
1
;
Zhenglin YANG
Author Information
1. 中国科学院大学成都生物研究所 四川省人民医院眼科 610072
- From:
Chinese Journal of Ocular Fundus Diseases
2020;36(2):156-161
- CountryChina
- Language:Chinese
-
Abstract:
Wet age-related macular degeneration (wAMD) is caused by choroidal neovascularization (CNV), which occurs when the choroidal new capillaries reach the RPE layer and photoreceptor cell layer through the ruptured Bruch membrane, leading to neovascularization bleeding, leakage, and scarring. In view of the important role of VEGF in the development of CNV, targeted therapy with various intraocular anti-VEGF drugs is the first-line treatment for wAMD. However, the efficacy of anti-VEGF drugs in the treatment of wAMD is affected by a variety of factors, and some patients still have problems such as unresponsiveness, drug resistence, tachyphylaxis, long-term repeated injections, and severe adverse effects. It is the direction of future researches to deeply explore the physiological and pathological process of wAMD, find the cause of CNV formation, and seek better therapies.
